<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01321333</url>
  </required_header>
  <id_info>
    <org_study_id>CL-N02-SC</org_study_id>
    <nct_id>NCT01321333</nct_id>
  </id_info>
  <brief_title>Study of Human Central Nervous System Stem Cells (HuCNS-SC) in Patients With Thoracic Spinal Cord Injury</brief_title>
  <official_title>A Phase I/II Study of the Safety and Preliminary Efficacy of Intramedullary Spinal Cord Transplantation of Human Central Nervous System (CNS) Stem Cells (HuCNS-SCÂ®) in Subjects With Thoracic (T2-T11) Spinal Cord Trauma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>StemCells, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>StemCells, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will evaluate the effect of single transplantation of HuCNS-SC cells into the
      thoracic spinal cord of patients with sub-acute spinal cord injury.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study subjects will receive immunosuppression for nine months following transplantation. All
      enrolled subjects will be followed for one year following transplantation and then will be
      enrolled in a separate long-term follow-up study for an additional four years.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>March 2011</start_date>
  <completion_date type="Actual">April 2015</completion_date>
  <primary_completion_date type="Actual">April 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Types and frequencies of adverse events and serious adverse events</measure>
    <time_frame>One year after transplant</time_frame>
    <description>Analysis of types and frequencies of adverse events one year after transplant.</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">12</enrollment>
  <condition>Thoracic Spinal Cord Injury</condition>
  <condition>Spinal Cord Injury</condition>
  <condition>Spinal Cord Injury Thoracic</condition>
  <condition>Spinal Cord Trauma</condition>
  <arm_group>
    <arm_group_label>HuCNS-SC cells</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Single dose intramedullary administration of HuCNS-SC cells</description>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>HuCNS-SC cells</intervention_name>
    <description>single dose intramedullary transplantation of HuCNS-SC cells in the thoracic spinal cord</description>
    <arm_group_label>HuCNS-SC cells</arm_group_label>
    <other_name>Human central nervous system stem cells</other_name>
    <other_name>allogeneic stem cells</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  T2-T11 thoracic spinal cord injury based on American Spinal Injury Association (ASIA)
             level determination by the principal investigator (PI)

          -  T2-T11 thoracic spinal cord injury as assessed by magnetic resonance imaging (MRI)
             and/or computerized tomography (CT)

          -  ASIA Impairment Scale (AIS) Grade A, B, or C

          -  Minimum of six weeks post injury for the initiation of screening

          -  Must have evidence of preserved conus function

          -  Must be at stable stage of medical recovery after injury

        Exclusion Criteria:

          -  History of traumatic brain injury without recovery

          -  Penetrating spinal cord injury

          -  Evidence of spinal instability or persistent spinal stenosis and/or compression
             related to initial trauma

          -  Previous organ, tissue or bone marrow transplantation

          -  Previous participation in any gene transfer or cell transplant trial

          -  Current or prior malignancy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen Huhn, MD</last_name>
    <role>Study Chair</role>
    <affiliation>StemCells, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N-2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital Balgrist- Uniklinik Balgrist, Forschstrasse 340</name>
      <address>
        <city>Zurich</city>
        <zip>8008</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 21, 2011</study_first_submitted>
  <study_first_submitted_qc>March 22, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">March 23, 2011</study_first_posted>
  <last_update_submitted>June 16, 2015</last_update_submitted>
  <last_update_submitted_qc>June 16, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 18, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>thoracic spinal cord injury</keyword>
  <keyword>spinal cord injury thoracic</keyword>
  <keyword>sub-acute spinal cord injury</keyword>
  <keyword>human neural stem cells</keyword>
  <keyword>stem cells</keyword>
  <keyword>stem cells transplant</keyword>
  <keyword>stem cells transplant spinal cord injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Wounds and Injuries</mesh_term>
    <mesh_term>Spinal Cord Injuries</mesh_term>
    <mesh_term>Thoracic Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

